万泰生物(603392.SH)涨超6%，九价HPV疫苗首次获得批签发证明

Core Viewpoint - Wantai Biological Pharmacy's subsidiary has received approval for its nine-valent HPV vaccine, marking a significant milestone for the company as it officially enters the market, enhancing its product lineup and potential revenue streams [1] Group 1: Company Developments - Wantai Biological's stock surged over 6%, reaching 61.08 yuan, with trading volume expanding to nearly 700 million yuan [1] - The nine-valent HPV vaccine produced by Xiamen Wantai Canghai Biological Technology Co., Ltd. has been granted a "Biological Product Batch Release Certificate" by the China Food and Drug Administration [1] - The approval of the nine-valent HPV vaccine is expected to strengthen the company's profitability and market competitiveness, solidifying its market position [1]